Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT00161031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00161031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
Lead sponsor
University of Maryland, Baltimore
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2004
Completion date
December 31, 2006
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia